Johnson & Johnson (NYSE:JNJ) Shares Sold by Curbstone Financial Management Corp

Posted by Defense World Staff on Mar 30th, 2023

Curbstone Financial Management Corp lessened its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 28,046 shares of the company’s stock after selling 384 shares during the quarter. Johnson & Johnson makes up 1.2% of Curbstone Financial Management Corp’s holdings, making the stock its 22nd biggest position. Curbstone Financial Management Corp’s holdings in Johnson & Johnson were worth $4,954,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in JNJ. Vanguard Group Inc. lifted its holdings in Johnson & Johnson by 1.2% during the third quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock valued at $40,078,885,000 after purchasing an additional 2,815,655 shares in the last quarter. State Street Corp lifted its holdings in Johnson & Johnson by 0.6% during the third quarter. State Street Corp now owns 141,886,311 shares of the company’s stock valued at $23,178,548,000 after purchasing an additional 803,013 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Johnson & Johnson by 3.3% during the third quarter. Price T Rowe Associates Inc. MD now owns 25,428,626 shares of the company’s stock valued at $4,154,022,000 after purchasing an additional 805,831 shares in the last quarter. Legal & General Group Plc lifted its holdings in Johnson & Johnson by 2.3% during the second quarter. Legal & General Group Plc now owns 18,839,914 shares of the company’s stock valued at $3,344,295,000 after purchasing an additional 421,779 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Johnson & Johnson by 1.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company’s stock valued at $3,046,449,000 after purchasing an additional 328,297 shares in the last quarter. Institutional investors and hedge funds own 67.94% of the company’s stock.

Johnson & Johnson Price Performance

Shares of JNJ opened at $153.31 on Thursday. Johnson & Johnson has a 1-year low of $150.11 and a 1-year high of $186.69. The stock has a market cap of $399.26 billion, a PE ratio of 22.75, a P/E/G ratio of 2.63 and a beta of 0.54. The firm has a 50-day simple moving average of $158.62 and a two-hundred day simple moving average of $167.29. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.99 and a quick ratio of 0.77.

Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, beating analysts’ consensus estimates of $2.22 by $0.13. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. The business had revenue of $23.71 billion during the quarter, compared to analysts’ expectations of $23.90 billion. During the same period last year, the business earned $2.13 earnings per share. The business’s revenue for the quarter was down 4.4% on a year-over-year basis. As a group, analysts forecast that Johnson & Johnson will post 10.5 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st were issued a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.95%. The ex-dividend date was Friday, February 17th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 67.06%.

Insider Activity at Johnson & Johnson

In related news, insider James D. Swanson sold 1,062 shares of Johnson & Johnson stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the completion of the transaction, the insider now owns 9,215 shares in the company, valued at $1,425,191.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.35% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. StockNews.com assumed coverage on shares of Johnson & Johnson in a research note on Thursday, March 16th. They issued a “strong-buy” rating on the stock. SVB Leerink decreased their price target on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a research note on Friday, January 20th. Citigroup raised their price target on shares of Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a research note on Monday, December 12th. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, February 1st. Finally, Piper Sandler decreased their price target on shares of Johnson & Johnson from $55.00 to $52.00 in a research note on Monday, February 6th. Eight investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $173.67.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.